Browsing Tag
Ulixacaltamide
3 posts
Could essential tremor finally be entering a new treatment era after Praxis’ Phase 3 results?
Praxis Precision Medicines’ Phase 3 results could reshape essential tremor treatment and re-rate the neurology market. Read what this means for investors.
Praxis Precision Medicines (NASDAQ: PRAX) surges 229% after breakthrough Phase 3 data in essential tremor
Praxis stock soared 229% on Phase 3 results for ulixacaltamide in essential tremor. Find out what this means for PRAX’s future and investor sentiment.
Praxis Precision Medicines faces major setback in ulixacaltamide trial but remains committed to Essential3 study
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company specializing in treatments for central nervous system disorders, encountered…